Stocks TelegraphStocks Telegraph
Stock Ideas

PYXS Financial Statements and Analysis

NASDAQ : PYXS

Pyxis Oncology

$3.04
0.39+14.72%
At Close 4:00 PM
55.38
B-ESG ScoreESG Rating

FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

DateMar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20262025202520252024
periodQ1Q3Q2Q1Q3
revenue002.82M00
cost of revenue459.00K0000
gross profit-459.00K02.82M00
gross profit ratio001.0000
research and development expenses19.595M17.808M17.133M17.044M17.741M
general and administrative expenses4.377M5.653M5.437M5.87M6.013M
selling and marketing expenses0-684.00K000
selling general and administrative expenses4.377M4.969M5.437M5.87M6.013M
other expenses-71.00K684.00K000
operating expenses23.901M23.461M22.57M22.914M23.754M
cost and expenses24.36M23.461M22.57M22.914M23.754M
interest income457.00K774.00K995.00K1.241M1.846M
interest expense00000
depreciation and amortization459.00K535.00K535.00K552.00K731.00K
ebitda-22.813M-21.468M-19.215M-22.362M-23.023M
ebitda ratio00-6.81400
operating income-24.36M-23.461M-19.75M-22.914M-23.754M
operating income ratio00-7.00400
total other income expenses net1.088M1.458M1.679M1.756M2.551M
income before tax-23.272M-22.003M-18.071M-21.158M-21.203M
income before tax ratio00-6.40800
income tax expense00283.00K00
net income-23.272M-22.003M-18.354M-21.158M-21.203M
net income ratio00-6.50900
eps-0.37-0.35-0.30-0.35-0.35
eps diluted-0.37-0.35-0.30-0.35-0.35
weighted average shs out63.47M62.557M61.919M61.049M60.715M
weighted average shs out dil63.47M62.557M61.919M61.049M60.715M
Graph

Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

DateMar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20262025202520252024
periodQ1Q3Q2Q1Q3
cash and cash equivalents7.238M10.391M10.733M12.759M12.056M
short term investments35.252M67.337M78.211M92.673M132.762M
cash and short term investments42.49M77.728M88.944M105.432M144.818M
net receivables003.00M00
inventory00000
other current assets3.082M5.345M8.012M6.439M4.05M
total current assets45.572M83.073M99.956M111.871M148.868M
property plant equipment net18.728M20.097M20.771M21.452M22.824M
goodwill00000
intangible assets02.434M2.488M023.619M
goodwill and intangible assets02.434M2.488M2.544M23.619M
long term investments00000
tax assets00000
other non current assets00000
total non current assets18.728M22.531M23.259M23.996M46.443M
other assets00000
total assets64.30M105.604M123.215M135.867M195.311M
account payables4.989M9.756M9.412M2.846M4.87M
short term debt1.757M1.63M1.568M1.508M1.393M
tax payables00000
deferred revenue00000
other current liabilities9.786M7.996M6.698M10.076M14.057M
total current liabilities16.532M19.382M17.678M14.43M20.32M
long term debt16.50M17.443M17.894M18.334M19.147M
deferred revenue non current00000
deferred tax liabilities non current00002.164M
other non current liabilities00000
total non current liabilities16.50M17.443M17.894M18.334M21.311M
other liabilities00000
capital lease obligations0019.462M19.842M20.54M
total liabilities33.032M36.825M35.572M32.764M41.631M
preferred stock00000
common stock63.00K62.00K62.00K62.00K59.00K
retained earnings-466.449M-425.071M-403.068M-384.714M-327.985M
accumulated other comprehensive income loss069.00K-5.00K49.00K351.00K
other total stockholders equity497.654M493.719M490.654M487.706M481.255M
total stockholders equity31.268M68.779M87.643M103.103M153.68M
total equity31.268M68.779M87.643M103.103M153.68M
total liabilities and stockholders equity64.30M105.604M123.215M135.867M195.311M
minority interest00000
total investments35.252M67.337M78.211M92.673M132.762M
total debt18.257M19.073M19.462M19.842M20.54M
net debt11.019M8.682M8.729M7.083M8.484M
Graph

Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

DateMar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Jun 30, 2024
reported currencyUSDUSDUSDUSDUSD
calendar year20262025202520252024
periodQ1Q3Q2Q1Q2
deferred income tax00000
stock based compensation1.21M03.015M3.631M2.871M
change in working capital-4.386M5.448M-1.765M-4.596M12.365M
accounts receivables00-3.00M08.00M
inventory00000
accounts payables-5.896M344.00K6.566M-2.013M3.177M
other working capital1.51M5.104M-5.331M-2.583M1.188M
other non cash items-11.00K2.751M-694.00K-964.00K-601.00K
net cash provided by operating activities-26.00M-13.277M-17.263M-22.535M-2.945M
investments in property plant and equipment0-9.00K000
acquisitions net00000
purchases of investments-10.992M-14.557M-41.096M-51.352M-39.312M
sales maturities of investments27.361M26.037M56.40M67.173M39.316M
other investing activites00004.00K
net cash used for investing activites16.369M11.471M15.304M15.821M4.00K
debt repayment0000-62.00K
common stock issued0002.00K153.00K
common stock repurchased00-67.00K0-43.00K
dividends paid00000
other financing activites-25.00K-8.00K0-2.00K-43.00K
net cash used provided by financing activities-25.00K-8.00K-67.00K048.00K
effect of forex changes on cash00000
net change in cash-9.656M-1.814M-2.026M-6.714M-2.893M
cash at end of period7.238M10.391M12.205M14.231M26.546M
cash at beginning of period16.894M12.205M14.231M20.945M29.439M
operating cashflow-26.00M-13.277M-17.263M-22.535M-2.945M
capital expenditure0-9.00K000
free cash flow-26.00M-13.286M-17.263M-22.535M-2.945M
Graph

Frequently Asked Questions

How did Pyxis Oncology, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?
A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, PYXS generated $0.00 in revenue last quarter, while its costs came in at $459.00K.
Last quarter, how much Gross Profit did Pyxis Oncology, Inc. report?
A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Pyxis Oncology, Inc. reported a -$459.00K Gross Profit for the quarter ended Mar 31, 2026.
Have PYXS's Total Operating Expenses and Operating Income been favorable recently?
Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. PYXS incurred $23.90M worth of Operating Expenses, while it generated -$24.36M worth of Operating Income.
How much Net Income has PYXS posted recently?
The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Pyxis Oncology, Inc., the company generated -$23.27M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.
At the end of the last quarter, how much Cash and Equivalents did Pyxis Oncology, Inc. have?
The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Pyxis Oncology, Inc. as of the end of the last quarter was $7.24M.
What are PYXS's Total Net Receivables for the last quarter?
Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, PYXS had Total Net Receivables of $0.00.
In terms of Total Assets and Current Assets, where did Pyxis Oncology, Inc. stand at?
An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of PYXS were $45.57M, while the Total Assets stand at $64.30M.
As of the last quarter, how much Total Debt did Pyxis Oncology, Inc. have?
The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of PYXS's debt was $18.26M at the end of the last quarter.
What were PYXS's Total Liabilities during the last reported quarter?
A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, PYXS reported total liabilities of $33.03M.
How much did PYXS's Working Capital change over the last quarter?
Working Capital Change for PYXS was -$4.39M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.
PYXS generated how much cash from operating activities?
An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. PYXS generated -$26.00M of Cash from Operating Activities during its recently reported quarter.
What was PYXS's latest reported Net Change in Cash?
An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. PYXS reported a -$9.66M Net Change in Cash in the most recent quarter.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph